AAV2/8 vector-mediated liver gene therapy for phenylketonuria (PKU)

AAV2/8 载体介导的苯丙酮尿​​症 (PKU) 肝脏基因治疗

• 批准号: 7390617
• 负责人: Cary O. Harding
• 金额: $ 27.97万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2010-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7390617
• 关键词: Adolescent; Adverse effects; Ally; Animals; Biochemical; Capsid; Cells; Chronic; Complementary DNA; Condition; Development; Disease; Dose; Enzymes; Evaluation; Frequencies; Gene Expression; Gene Transfer; Gene Transfer Techniques; Goals; Growth; Hepatocyte; Human; Hyperphenylalaninaemias; Immune response; Inborn Errors of Metabolism; Incidence; Inherited; Injection of therapeutic agent; Investigation; Learning; Life; Liver; Measures; Mediating; Metabolic Clearance Rate; Methods; Modeling; Mus; Mutation; Numbers; Outcome; Phenotype; Phenylalanine; Phenylalanine Hydroxylase; Phenylalanine Metabolism Pathway; Physiological; Play; Portal vein structure; Proteins; Rate; Recombinant adeno-associated virus (rAAV); Role; Safety; Serotyping; Serum; Site; Tail; Testing; Therapeutic; Tissues; Transcriptional Regulation; Transplantation; Treatment Efficacy; Veins; Week; cytotoxic; design; efficacy evaluation; enzyme activity; enzyme deficiency; gene therapy; immunogenicity; improved; infancy; mouse model; novel; promoter; research study; restoration; success; therapeutic gene; trial comparing; vector; vector genome

DESCRIPTION (provided by applicant): Liver-directed gene therapy is a promising approach to the treatment of human inborn errors of metabolism (IEM) due to specific liver enzyme deficiencies. The goal of this project is to develop a safe, effective liver- directed gene transfer technique for IEM by treating phenylalanine hydroxylase (PAH)-deficient Pahenu2 mice, a model of human phenylketonuria (PKU). We have recently witnessed complete correction of serum phenylalanine levels in Pahenu2 mice treated with a novel recombinant adeno-associated virus serotype 2 vector pseudotyped with serotype 8 capsid (rAAV2/8). We plan to extend this observation to evaluate long- term stability and incidence of adverse effects following rAAV2/8 administration and to further our understanding of the physiologic factors that govern phenylalanine clearance. Our specific hypothesis is that complete correction of hyperphenylalaninemia and its attendant phenotypic features will require permanent restoration of liver PAH activity in at least 10% of Pahenu2 hepatocytes. In the first aim of the project, we will investigate the physiologic thresholds that govern phenylalanine clearance in murine liver. We will transplant primary hepatocytes under a selective growth advantage into PAH deficient mice and will accurately determine the number of PAH positive hepatocytes and absolute amount of PAH enzyme activity required to correct hyperphenylalaninemia. Transplantation of hepatocytes that are either wild type and therefore express 100% normal PAH activity or are heterozygous for the Pahenu2 mutation and have < 100% PAH activity will allow us to determine the interrelationship between liver PAH activity, the absolute number of PAH-expressing cells and total phenylalanine clearance. In the second aim, we will fully evaluate the efficacy and safety of rAAV2/8-mediated, liver-directed gene transfer as therapy for murine PKU. We will evaluate transduction frequency, the amount and duration of therapeutic gene expression, the effect of therapy upon physical and biochemical phenotypes of the mice, the frequency of vector integration, and the incidence of adverse effects in the animals following treatment with rAAV2/8. Our ultimate goal is to develop an effective liver-directed gene transfer method for the treatment of murine PKU. We propose that lessons learned from the treatment of murine PKU will ultimately be applicable to the treatment of human PKU and other allied IEM.

描述(由申请人提供)： 肝脏导向基因治疗是治疗由于特异性肝酶缺乏所致的先天性代谢障碍(IEM)的一种很有前途的方法。本项目的目标是通过治疗苯丙氨酸羟化酶(PAH)缺陷的Pahenu2小鼠(人苯丙酮尿症(PKU)的模型)，开发一种安全、有效的IEM基因转移技术。我们最近观察到，用一种新型重组腺相关病毒8型衣壳伪型载体(rAAV2/8)治疗Pahenu2小鼠后，血清苯丙氨酸水平完全纠正。我们计划将这一观察扩展到评估rAAV2/8给药后的长期稳定性和不良反应的发生率，并进一步了解控制苯丙氨酸清除的生理因素。我们的特定假设是，完全纠正高苯丙氨酸血症及其伴随的表型特征将需要至少10%的Pahenu2肝细胞永久恢复肝脏PAH活性。在该项目的第一个目标中，我们将调查控制小鼠肝脏苯丙氨酸清除的生理阈值。我们将在选择性生长优势下将原代肝细胞移植到PAH缺陷小鼠体内，并准确测定纠正高苯丙氨酸血症所需的PAH阳性肝细胞的数量和PAH酶的绝对量。如果移植的肝细胞是野生型，因此表达100%正常的PAH活性，或者是Pahenu2突变的杂合子，并且具有100%的PAH活性，那么我们就可以确定肝脏PAH活性、表达PAH的细胞的绝对数量和苯丙氨酸总清除量之间的相互关系。在第二个目标中，我们将充分评价rAAV2/8介导的、肝脏导向的基因转移作为治疗小鼠PKU的有效性和安全性。我们将评估转导频率、治疗性基因表达的数量和持续时间、治疗对小鼠生理生化表型的影响、载体整合的频率以及rAAV2/8治疗后动物的不良反应发生率。我们的最终目标是建立一种有效的肝脏导向基因转移方法来治疗小鼠PKU。我们认为，从小鼠PKU治疗中吸取的经验教训最终将适用于人类PKU和其他相关IEM的治疗。